NovaBay Pharmaceuticals’ Bold Transformation to Digital Asset Treasury

Legacy Business Performance and Eventual Divestitures

NovaBay Pharmaceuticals’ historical footprint centered on the development and commercialization of clinically proven eyecare and wound care products. The company’s revenue trajectory tells a story of steep contraction: from approximately $11 million reported in FY2011 down to just $370 thousand in FY2014 [F1]. This precipitous decline underscored the gradual wind-down of operating activities prior to a definitive strategic transformation.

By early 2025, NovaBay had completed comprehensive divestitures of its legacy assets across three key transactions: the Avenova Asset Divestiture (January 2025), PhaseOne Divestiture (January 2025), and DERMAdoctor Divestiture (timing aligned) [S1][S11]. These divestitures marked the exit from most revenue-generating operations linked to pharmaceutical product manufacturing and sales.

Financially, the impact manifested starkly: FY2025 operating income was a negative $8.44 million (-44.5% YoY vs FY2024), while net losses expanded dramatically to $22.14 million (-206% YoY) [F1]. Operating cash flow remained deeply negative at -$8.43 million in FY2025, surpassing prior years’ deficits and reflecting costs sustained during the transition phase [F1]. Capital expenditures were minimal at about $6 thousand in FY2024 reflecting near-cessation of R&D and manufacturing investments [F1][S8].

These figures illustrate an operational wind-down rather than growth dynamics, with legacy pharmaceutical revenue effectively collapsing and ongoing operating expenses concentrated on administrative realignment rather than product development or sales.

Historical performance (annual)

Source: SEC companyfacts cache [F1].

Capital returns and efficiency (annual)

Source: SEC companyfacts cache [F1].

Note: Earlier years presented subject to data availability; revenue for recent years effectively zero or reclassified due to discontinued operations.

Transition Catalysts: Why and How NovaBay Shifted Focus

The strategic reset emerged against this backdrop of operational contraction and financial deterioration. In January 2026, NovaBay completed a pivotal private placement which generated approximately $137.4 million comprising $25 million cash plus roughly $112.4 million in SKY tokens and stablecoins [S1]. This transaction marked the formal embrace of a blockchain-based asset treasury model.

Management articulated that the new mandate focuses on capital allocation into digital assets granting "economic participation within open digital financial networks," centering exclusively on the Sky Protocol’s native token — SKY [S1]. The priority is to strategically acquire SKY tokens as long-term holdings aimed at benefiting from staking rewards and potential protocol appreciation.

Governance adjustments coincided with this shift: CEO David Lazar resigned in October 2025 amidst major preferred stock transactions involving Framework Ventures entities who assumed material ownership stakes thereafter [S3][S5]. This enhanced governance involvement aligns with the nascent Digital Asset Strategy Advisory Committee tasked with managing risk frameworks related to these novel investments.

The rationale for this pivot included recognition of limited growth prospects within legacy markets due to intense competition and dispossession of intellectual property via recent divestitures [S8], prompting transformation into a treasury-centric entity seeking scalable exposure via innovative decentralized finance mechanisms.

Digital Asset Strategy: SKY Tokens as Core Treasury Assets

NovaBay’s treasury now holds an aggregate position exceeding approximately 944 million SKY tokens following initial grants around the January 2026 placement [S1][S22]. These tokens reside within wallets secured by public/private key infrastructure consistent with industry best practices.

Custody arrangements are provided by multiple US-based custodians adhering to rigorous internal controls designed to mitigate counterparty risks inherent in digital asset safekeeping [S1][S24]. These measures encompass encryption protocols as well as operational segregation between trading desks and custody services.

SKY operates on a proof-of-stake blockchain architecture enabling holders like NovaBay not only to participate passively via token appreciation but also actively through staking or delegation arrangements yielding network rewards [S1]. This participation introduces specialized protocol economics including inflationary token generation incentives but also exposes holders to smart contract vulnerabilities and network governance risks absent from traditional assets.

Risk frameworks explicitly account for evolving legal interpretations about whether SKY may constitute a security under U.S federal laws—a determination carrying compliance complexities especially regarding staking rewards or derivative contracts tied to SKY [S9][S26]. Furthermore, emergent regulatory structures across several states impose variable definitions on investment contracts associated with such digital holdings creating jurisdictional uncertainty over operational viability.

Analyzing Financial Impact and Historical Trends: From Revenue Collapse to Capital Redeployment

The financial picture is one transformed by contraction yet cushioned by capital infusion targeting new asset classes:

• Revenues dwindled sharply post-2014 exit from legacy pharma operations; absent meaningful ongoing sales after comprehensive divestitures.
• Operating losses intensified as legacy fixed costs relented slowly amidst realignment.
• Cash flows were consistently negative suggesting that operating burdens outpaced any liquidation proceeds until fortress liquidity was established via capital raises.
• Capex spending declined markedly reflecting cessation of R&D investment beyond maintenance phases.

This defensive retrenchment culminated in transitioning all available liquidity into digital assets characterized by high volatility but theoretically offering expansive upside tied to blockchain network dynamics.

Insight into Capital Structure, Equity Changes, and Cash Flow Dynamics

To facilitate this transformation NovaBay executed multiple financing rounds:

• In August 2025 entered preferred stock agreements raising ~$5.9 million from associated parties including Mr. Lazar before his exit [S5][S6].
• October 16, 2025 saw conversion of Series D and E Preferred Stock into common shares increasing equity base significantly ahead of further funding events [S15].
• January 16, 2026 private placement yielded gross proceeds approximating $137.4 million split among cash ($25M), stablecoins (~$51M converted promptly into USD), and nearly $61M valued SKY tokens [S1][S22].
• Post-placement deployment included approximately $70.7M cash acquisitions of additional SKY tokens up to March 16, 2026 enhancing strategic holdings [S6].

Current ratio approximates an outstanding ~7.6 indicating substantial short term liquidity available to cover liabilities—this bolsters operational runway through March 2027 per management estimates [F1][S6]. Nonetheless equity stands deeply negative at about -$23.2 million given accumulated losses exceeding residual shareholder value [F1].

Risk Landscape: Regulatory Ambiguity, Volatility, and Counterparty Challenges

NovaBay faces layered risk exposures unique to pioneering blockchain asset treasuries:

• Regulatory uncertainty looms over whether SK Ytokens or related staking services classify as securities per federal Howey test complexities; ambiguous guidance amplifies compliance risk [S9][S26].
• Custodial arrangements entail non-traditional counterparty risks; not all protections analogous to FDIC or SIPC insured instruments apply placing emphasis on internal controls integrity [S24].
• Market liquidity episodes could trigger widescale adverse price swings undermining valuation reliability for balance sheet representation or margin requirements [S23].
• Engagements within decentralized finance protocols potentially expose the Company to smart contract exploits or systemic failures unforeseen given proof-of-stake networks’ relatively young lifecycle compared to proof-of-work blockchains [S1][S9].
• Political or macroeconomic shocks inducing cryptocurrency sell-offs can exacerbate price volatility rising risk of capital impairment beyond normal market cycles [S27].

Additionally cyberattack risks threatening blockchain network integrity pose existential threats distinct from traditional financial markets impacting token value materially if successful attacks transpire [S1].

Future Outlook: Growth Potentials, Constraints, and Key Milestones to Monitor

Management refrains from issuing explicit earnings guidance but highlights strategic ambitions revolving around multi-year accumulation of SKY tokens balanced against risk appetite overseen by their Digital Asset Strategy Advisory Committee [S1][S3]. Growth vectors would primarily hinge on increasing protocol rewards streams through staking activities alongside potential appreciation in token market price.

Constraints include regulatory evolution likely imposing additional compliance costs or restricting staking participation practices—both bearing heavily on achievable returns versus risks borne. Volatility remains unavoidable given nascent nature of protocols involved impacting predictability of income generation.

Key milestones include:

• Regulatory clarity developments surrounding classification of SKY-related instruments impacting operational flexibility,
• Token price dynamics driven by adoption rates or technical upgrades,
• Capital market reactions influencing ability for aftermarket financings under ATM programs,
• Advisory committee decisions calibrating risk thresholds for further acquisitions versus monetization windows.

Tracking these factors will be essential for stakeholders seeking insight into NovaBay’s continued transition efficacy.

Capital Allocation Philosophy and Shareholder Returns Post-Transformation

Despite substantial losses reflected in negative equity and operating deficits reported in FY2025 [$22.14 million net loss], NovaBay maintained dividend distributions amounting to approximately $4.82 million during that period—a noteworthy decision signaling confidence in retained earnings sufficiency or commitment toward shareholder engagement amid difficult transitions[F1][S15]. Buyback activity disclosures since pivot remain absent indicating focus prioritizing reinvestment into digital assets over capital return via stock repurchases.

Overall return on equity metrics have deteriorated under negative profit conditions although management predicates future positive returns linked to digital asset appreciation potential rather than conventional profitability models prevailing under previous pharmaceutical business lines.

Disclaimer: This report is prepared solely for informational purposes based on publicly available data as of March 19, 2026. It does not constitute investment advice nor an offer or solicitation to buy or sell securities. Readers should conduct independent analysis considering their risk tolerance before engaging with NovaBay Pharmaceuticals' securities or strategies described herein.

Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.